News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma President Kevin Koch to Present at American Association for Cancer Research Meeting

BOULDER, Colo., March 19 /PRNewswire-FirstCall/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its President and Chief Scientific Officer, Kevin Koch, Ph.D., was invited to present at the 95th Annual Meeting of the American Association for Cancer Research in Orlando, Florida.

     Event:         95th Annual Meeting of the American Association for Cancer
                    Research
     Educational
     Session:       Research Paradigms in Anticancer Drug Discovery &
                    Development
     Presentation:  "ARRY-142886, a Novel and Highly Selective MEK Inhibitor
                    in Clinical Trials"
     Date:          Saturday, March 27, 2004
     Time:          2:15 p.m. Eastern Time
     Location:      Orange County Convention Center, Orlando, Florida

In addition, scientists from Array will be presenting four scientific posters on Tuesday, March 30 from 8 am to 12 pm-noon:

Abstract Number 3888
"ARRY-142886, a potent and selective MEK inhibitor: I) ATP-independent
inhibition results in high enzymatic and cellular selectivity"

Abstract Number 3889
"ARRY-142886, a potent and selective MEK inhibitor: II) Potency against
cellular MEK leads to inhibition of cellular proliferation and induction
of apoptosis in cell lines with mutant Ras or B-Raf"

Abstract Number 3890
"ARRY-142886, a potent and selective MEK inhibitor: III) Efficacy in
murine xenograft models correlates with decreased ERK phosphorylation"

Abstract Number 3891
"Preclinical development of ARRY-142886, a potent and selective MEK
inhibitor"

Please contact Tricia Haugeto at 303-386-1193, or thaugeto@arraybiopharma.com, if you are interested in receiving copies of the posters after they are presented.

About ARRY-142886 (AZD6244):

In December 2003, AstraZeneca AB acquired exclusive, worldwide rights to ARRY-142886 (AZD6244) and related intellectual property for oncology indications. Array recently filed an IND with the Food and Drug Administration and will be responsible for performing a Phase I clinical trial. AstraZeneca will be responsible for all other aspects of clinical development and commercialization.

About Array BioPharma:

Array BioPharma is creating the next generation of orally active drugs by integrating the latest advances in chemistry, biology and informatics. Our drug development pipeline is focused primarily in cancer and inflammatory disease and includes several promising small molecule drugs that regulate well-validated targets in therapeutically valuable disease pathways. Array collaborates with leading pharmaceutical and biotechnology companies to design, create and optimize drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

Founded in 1998, Array BioPharma is headquartered in Boulder, Colorado and employs over 250, including 200 scientists. Companies utilizing Array's drug discovery expertise include AstraZeneca, Genentech, Eli Lilly, InterMune, GenPath, Roche and Takeda.

SOURCE Array BioPharma Inc. 03/19/2004

CONTACT: Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, thaugeto@arraybiopharma.com

Web site: http://www.arraybiopharma.com